Ionis Pharmaceuticals (IONS) Misses Q2 EPS by 20c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Ionis Pharmaceuticals (IONS) PT Lowered to $47 at Stifel
August 9, 2018 6:24 AM EDTStifel lowered its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $47.00 (from $48.00) while maintaining a Hold rating.
... MoreStifel Transfers Coverage of Ionis Pharmaceuticals (IONS), Maintains Hold
August 6, 2018 4:19 PM EDTStifel assumes coverage on Ionis Pharmaceuticals (NASDAQ: IONS) with a Hold rating and a price target of $48.00.
Analyst Paul Matteis assumes coverage at Hold and lowers the PT to $48.00 (from $55.00)
For an analyst ratings summary and ratings history on Ionis Pharmaceuticals... More
